ABSTRACT
.» t.it work was designed to studytheprevalenceofglutamicacid
antibodies (GADab) in representatives ofEgyptianNIDDMpatients
‘
' thephenotypiccharacteristicsandHLAtypesofthissubgroup.
,
I dnon—insulintreatedtype2 diabeticpatients(GroupI),50insulin
‘ Jabeticpatients(GroupII)and50healthyvolunteersservingascontrols
constitutedthe subjectsofourstudy.Theageofpatientsrangedbetween
a otype wasassessedbypatient'sage,ageofonsetofdiabetes,bodymass
, plasma glucose, percentage hemoglobin AIc (Hb A1c), serum
serumtriglycerides andserumC-peptidelevel. GADabwasmeasured
method.ClassIHLA(I-ILA-AandB)andclassIIHLA(HLA-DR)types
».
r
4 usingcytotoxicitytest.
’ prevalence ofGADabwas20%amonggroup1patients,60%amonggroup
_ . and4%amongcontrols. TheGADabpositiv'epatientsweresignificantly
andexperienceddiabetes onsetatanearlieragecomparedwithGADab
patients. The GADab positive patients had lowerfastingC—peptide
'on in comparisonwith GADabnegativepatients.Withrespecttofeatures
a 'c syndrome, theGADabpositivepatients hadlowerBMI,lowerserum
“
. 1‘ lowerserumtriglycerides, higherplasmaglucoseandhigherHbA[c
-» with GADabnegative patients.ComparedwithGADabnegativepatients
ols, groupIIpatientshadanincreasedfrequencyofHLADR3andDR4
HerewerenodtflerencesbetweenNIDDMandnormalcontrolsinthefrequency
particularHLAantigen exceptforanincreasedfrequencyofHLAB18inboth
« Iand11patientsandincreasedfrequencyofHLADR?/DR4ingroup11patients.
Uteseresultssuggestthattype2diabetesisaheterogeneousdisorderincludingat
t 2majorsubgroupscharacterizedbyGADabandHLDR3/DR4types. |
